Management of Thymectomised Myasthenic Patients

  • W. A. Nix
  • H. Große-Höötmann
  • T. Kirchner
  • A. Marx


This prospective study followed-up fifty-six thymectomised patients with thymoma-and non thymoma-associated generalized myasthenia gravis for at least 2 years. To study the effect of thymectomy, no immunosuppression was given until needed after surgery. Forty-one percent patients with thymitis went into spontaneous remission, 37% after additional immunosuppression. Only 11% of patients with thymoma or an atrophic thymus went into spontaneous remission. This group proved difficult to be treated as within the remaining 89% over 40% improved only partially in their symptoms with immunosuppression. Within all groups it was possible to withhold without adverse effects immunosuppression until there was a definite clinical need for therapy. Early diagnosis of spontaneous remission improves considerably the quality of life, especially in young patients.


Remission Rate Thymic Carcinoma Spontaneous Remission Extensor Digitorum Communis Atrophic Thymus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remission following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry 1991; 54:406–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Evoli A, Batocchi AP, Provenzano C, Ricci E, Tonali P. Thymectomy in the treatment of myasthenia gravis: report of 247 patients. J Neurol 1988; 235(5):272–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Fujii N, Itoyama Y, Machi M, Goto I. Analysis of Prognostic Factors in Thymectomized Patients with Myasthenia Gravis — Correlation Between Thymic Lymphoid Cell Subsets and Postoperative Clinical Course. J Neurol Sci 1991; 105(2): 143–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Genkins G, Kornfeld P, Papatestas AE, Bender AN, Matta RJ. Clinical experience in more than 2000 patients with myasthenia gravis. Ann N Y Acad Sci 1987; 505(Review):500–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505. P 472–99(Review).PubMedCrossRefGoogle Scholar
  6. 6.
    Jaretzki AS, Penn AS, Younger DS etal. “Maximal” thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg 1988; 95:747–57.PubMedGoogle Scholar
  7. 7.
    Kirchner Th, Schalke B, Melms A, von Kügelgen T, Müller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch [Cell Pathol] 1986; 52:237–57.CrossRefGoogle Scholar
  8. 8.
    Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990; 40:1828–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Lindberg G, Andersen O, Larsson S, Oden A. Remission rate after thymectomy in myasthenia gravis when the bias of immunosupressive therapy is eliminated. Acta Neurol Scand 1992; 86:323–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Maggi G, Giaccone G, Donadio Metal. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer 1986; 58(3): 765–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Mantegazza R, Beghi E, Pareyson D etal. A multicenter follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990; 6:339–44.CrossRefGoogle Scholar
  12. 12.
    Müller-Hermelink HK, Marino M, Palestro G. Pathology of thymic epithelial tumors. Vol. 75. Berlin: Springer, 1986: 207-68. (Müller-Hermelink HK Ed; The Human Thymus: Histopathology and Pathology. Current Topics in Pathology).Google Scholar
  13. 13.
    Nix WA, Große-Höötmann H, Kirchner T, Marx A. Remission rate after thymectomy in myasthenia gravis. Neurology 1995; 45:A352–253.Google Scholar
  14. 14.
    Olanow CW, Lane RJM, Roses AD. Thymectomy in late-onset myasthenia gravis. Arch Neurol 1982; 39:82–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Oosterhuis HJ. Long-term effects of treatment in 374 patients with myasthenia gravis. Monogr Allergy. 1988; 25:75–85.PubMedGoogle Scholar
  16. 16.
    Oosterhuis HJGH. The Natural Course of Myasthenia Gravis — A Long Term Follow Up Study. J Neurol Neurosurg Psychiatry 1989; 52(10): 1121–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Paletto AE, Maggi G. Thymectomy in the treatment of myasthenia gravis: results in 320 patients. Int Surg 1982; 67:13–6.PubMedGoogle Scholar
  18. 18.
    Palmisani MP, Evoli A, Batocchi AP, Provenzano C, Tonali P. Myasthenia gravis associated with thymoma: Clinical characteristics and long-term outcome. Eur Neurol 1993; 34:78–82.CrossRefGoogle Scholar
  19. 19.
    Pan CH, Chiang CY, Chen SS. Thymolipoma in patients with myasthenia gravis: report of two cases and review. Acta Neurol Scand 1988; 78(1): 16–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • W. A. Nix
    • 1
  • H. Große-Höötmann
    • 1
  • T. Kirchner
    • 2
  • A. Marx
    • 3
  1. 1.Department of NeurologyUniversity ClinicMainzGermany
  2. 2.Department of PathologyUniversity of ErlangenGermany
  3. 3.Department of PathologyUniversity of WürzburgGermany

Personalised recommendations